Summit Therapeutics Inc. Deferred Tax Assets, Other
Summit Therapeutics Inc. (SMMT) had Deferred Tax Assets, Other of $711.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOther · last filed 2026-02-23
- 2025-12-31: Deferred Tax Assets, Other $711.00K.
- 2024-12-31: Deferred Tax Assets, Other $475.00K.
- 2023-12-31: Deferred Tax Assets, Other $1.32M; Deferred Tax Assets, Other as first filed $1.26M.
- 2022-12-31: Deferred Tax Assets, Other $2.05M; Deferred Tax Assets, Other as first filed $2.14M.
| Period end | Deferred Tax Assets, Other | Deferred Tax Assets, Other as first filed |
|---|---|---|
| 2025-12-31 | $711.00K 10-K · filed 2026-02-23 | |
| 2024-12-31 | $475.00K 10-K · filed 2026-02-23 | |
| 2023-12-31 | $1.32M 10-K · filed 2025-02-24 | $1.26M 10-K · filed 2024-02-20 |
| 2022-12-31 | $2.05M 10-K · filed 2024-02-20 | $2.14M 10-K · filed 2023-03-09 |
| 2021-12-31 | $1.48M 10-K · filed 2023-03-09 | |
| 2020-12-31 | $491.00K 10-K/A · filed 2022-12-21 | |
| 2019-12-31 | $34.00K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |